NEW YORK (GenomeWeb News) — Ingenuity Systems said yesterday that it has joined the Biomarkers Consortium, a public-private endeavor aimed at developing, discovering, and qualifying new biomarkers for drug development, preventive medicine, and medical diagnostics.
The consortium was founded by the Foundation for the National Institutes of Health, the National Institutes of Health, the US Food and Drug Administration, the Centers for Medicare and Medicaid Services, and the Pharmaceutical Research and Manufacturers of America. It now comprises around 30 partners, including companies, patient advocacy organizations, government groups, and non-profits.
The consortium this summer launched a website that offers more information, accepts proposals for projects, and offers information on funding opportunities.
Ingenuity makes pathway analysis and knowledge-base software that helps researchers explore, analyze, and interpret scientific literature and data.